USBC, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that USBC, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Sep 30, 2023 | $0 | Dec 19, 2023 |
| FY2023 | Sep 30, 2022 | $4.36M | Dec 19, 2023 |
| FY2022 | Sep 30, 2021 | $0 | Dec 20, 2022 |
| FY2021 | Sep 30, 2020 | $121.9K | Dec 21, 2021 |
| FY2020 | Sep 30, 2019 | $1.80M | Dec 29, 2020 |
| FY2019 | Sep 30, 2018 | $4.30M | Dec 27, 2019 |
| FY2018 | Sep 30, 2017 | $4.87M | Dec 21, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Sep 30, 2021 | $0 | Dec 21, 2021 |
| FY2021 | Sep 30, 2020 | $52.2K | Dec 21, 2021 |
| FY2020 | Sep 30, 2019 | $426.5K | Dec 29, 2020 |
| FY2019 | Sep 30, 2018 | $821.6K | Dec 27, 2019 |
| FY2018 | Sep 30, 2017 | $907.8K | Dec 21, 2018 |
| FY2017 | Sep 30, 2016 | $987.9K | Dec 29, 2017 |
| FY2016 | Sep 30, 2015 | $1.02M | Jun 5, 2017 |
| FY2015 | Sep 30, 2014 | $1.29M | Nov 4, 2015 |
| FY2014 | Sep 30, 2013 | $1.86M | Jan 13, 2015 |
| FY2013 | Sep 30, 2012 | $1.58M | Jan 13, 2014 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($27.46M) | Mar 25, 2026 |
| FY2025 | Sep 30, 2025 | ($22.12M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($4.67M) | Mar 25, 2026 |
| FY2025 | Sep 30, 2024 | ($16.58M) | Mar 25, 2026 |
| FY2024 | Sep 30, 2023 | ($15.29M) | Nov 14, 2024 |
| FY2023 | Sep 30, 2022 | ($20.07M) | Dec 19, 2023 |
| FY2022 | Sep 30, 2021 | ($25.36M) | Dec 20, 2022 |
| FY2021 | Sep 30, 2020 | ($13.56M) | Dec 21, 2021 |
| FY2020 | Sep 30, 2019 | ($7.61M) | Dec 29, 2020 |
| FY2019 | Sep 30, 2018 | ($3.26M) | Dec 27, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($17.13M) | Mar 25, 2026 |
| FY2025 | Sep 30, 2025 | ($18.05M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($2.77M) | Mar 25, 2026 |
| FY2025 | Sep 30, 2024 | ($15.22M) | Mar 25, 2026 |
| FY2024 | Sep 30, 2023 | ($14.02M) | Nov 14, 2024 |
| FY2023 | Sep 30, 2022 | ($12.57M) | Dec 19, 2023 |
| FY2022 | Sep 30, 2021 | ($10.45M) | Dec 20, 2022 |
| FY2021 | Sep 30, 2020 | ($6.83M) | Dec 21, 2021 |
| FY2020 | Sep 30, 2019 | ($5.01M) | Dec 29, 2020 |
| FY2019 | Sep 30, 2018 | ($2.26M) | Dec 27, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $253.6K | Mar 25, 2026 |
| FY2025 | Sep 30, 2025 | $1.75M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $802.1K | Mar 25, 2026 |
| FY2025 | Sep 30, 2024 | $6.11M | Mar 25, 2026 |
| FY2024 | Sep 30, 2023 | $7.73M | Nov 14, 2024 |
| FY2023 | Sep 30, 2022 | $5.39M | Dec 19, 2023 |
| FY2022 | Sep 30, 2021 | $3.97M | Dec 20, 2022 |
| FY2021 | Sep 30, 2020 | $2.03M | Dec 21, 2021 |
| FY2020 | Sep 30, 2019 | $1.26M | Dec 29, 2020 |
| FY2019 | Sep 30, 2018 | $570.5K | Dec 27, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.87M | Mar 25, 2026 |
| FY2025 | Sep 30, 2025 | $16.29M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.97M | Mar 25, 2026 |
| FY2025 | Sep 30, 2024 | $9.11M | Mar 25, 2026 |
| FY2024 | Sep 30, 2023 | $6.57M | Nov 14, 2024 |
| FY2023 | Sep 30, 2022 | $8.12M | Dec 19, 2023 |
| FY2022 | Sep 30, 2021 | $6.48M | Dec 20, 2022 |
| FY2021 | Sep 30, 2020 | $4.84M | Dec 21, 2021 |
| FY2020 | Sep 30, 2019 | $4.18M | Dec 29, 2020 |
| FY2019 | Sep 30, 2018 | $2.51M | Dec 27, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.63M) | Mar 25, 2026 |
| FY2025 | Sep 30, 2025 | ($7.60M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($1.90M) | Mar 25, 2026 |
| FY2025 | Sep 30, 2024 | ($12.83M) | Mar 25, 2026 |
| FY2024 | Sep 30, 2023 | ($10.35M) | Nov 14, 2024 |
| FY2023 | Sep 30, 2022 | ($6.92M) | Dec 19, 2023 |
| FY2022 | Sep 30, 2021 | ($6.85M) | Dec 20, 2022 |
| FY2021 | Sep 30, 2020 | ($3.91M) | Dec 21, 2021 |
| FY2020 | Sep 30, 2019 | ($3.10M) | Dec 29, 2020 |
| FY2019 | Sep 30, 2018 | ($1.12M) | Dec 27, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 25, 2026 |
| FY2025 | Sep 30, 2025 | $0 | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 25, 2026 |
| FY2025 | Sep 30, 2024 | $66.4K | Mar 25, 2026 |
| FY2024 | Sep 30, 2023 | $80.8K | Nov 14, 2024 |
| FY2023 | Sep 30, 2022 | $855.5K | Dec 19, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $93.67M | Mar 25, 2026 |
| FY2025 | Sep 30, 2025 | $125.08M | Mar 25, 2026 |
| FY2025 | Sep 30, 2024 | $3.66M | Dec 19, 2025 |
| FY2024 | Sep 30, 2023 | $8.27M | Nov 14, 2024 |
| FY2023 | Sep 30, 2022 | $13.76M | Dec 19, 2023 |
| FY2022 | Sep 30, 2021 | $12.89M | Dec 20, 2022 |
| FY2021 | Sep 30, 2020 | $4.68M | Dec 21, 2021 |
| FY2020 | Sep 30, 2019 | $2.64M | Dec 29, 2020 |
| FY2019 | Sep 30, 2018 | $2.10M | Dec 27, 2019 |
| FY2018 | Sep 30, 2017 | $1.19M | Dec 21, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.14M | Mar 25, 2026 |
| FY2025 | Sep 30, 2025 | $27.96M | Mar 25, 2026 |
| FY2025 | Sep 30, 2024 | $5.82M | Dec 19, 2025 |
| FY2024 | Sep 30, 2023 | $4.52M | Nov 14, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $81.53M | Mar 25, 2026 |
| FY2025 | Sep 30, 2025 | $97.12M | Mar 25, 2026 |
| FY2025 | Sep 30, 2024 | ($2.16M) | Mar 25, 2026 |
| FY2025 | Sep 30, 2023 | $3.74M | Mar 25, 2026 |
| FY2024 | Sep 30, 2022 | $9.86M | Nov 14, 2024 |
| FY2023 | Sep 30, 2021 | $1.24M | Dec 19, 2023 |
| FY2022 | Sep 30, 2020 | ($1.91M) | Dec 20, 2022 |
| FY2021 | Sep 30, 2019 | ($3.30M) | Dec 21, 2021 |
| FY2020 | Sep 30, 2018 | ($2.61M) | Dec 29, 2020 |
| FY2019 | Sep 30, 2017 | ($3.96M) | Dec 27, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Sep 30, 2017 | $0 | Dec 29, 2017 |
| FY2017 | Sep 30, 2016 | $983.6K | Dec 29, 2017 |
| FY2016 | Sep 30, 2015 | $983.6K | Jun 5, 2017 |
| FY2015 | Sep 30, 2014 | $983.6K | Nov 4, 2015 |
| FY2014 | Sep 30, 2013 | $983.6K | Jan 13, 2015 |
| FY2013 | Sep 30, 2012 | $983.6K | Jan 13, 2014 |
| FY2012 | Sep 30, 2011 | $983.6K | Nov 13, 2012 |
| FY2011 | Sep 30, 2010 | $983.6K | Nov 30, 2011 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($190.55M) | Mar 25, 2026 |
| FY2025 | Sep 30, 2025 | ($163.09M) | Mar 25, 2026 |
| FY2025 | Sep 30, 2024 | ($138.74M) | Dec 19, 2025 |
| FY2024 | Sep 30, 2023 | ($121.84M) | Nov 14, 2024 |
| FY2023 | Sep 30, 2022 | ($101.40M) | Dec 19, 2023 |
| FY2022 | Sep 30, 2021 | ($81.33M) | Dec 20, 2022 |
| FY2021 | Sep 30, 2020 | ($55.97M) | Dec 21, 2021 |
| FY2020 | Sep 30, 2019 | ($42.40M) | Dec 29, 2020 |
| FY2019 | Sep 30, 2018 | ($34.79M) | Dec 27, 2019 |
| FY2018 | Sep 30, 2017 | ($31.53M) | Dec 21, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.10M | Mar 25, 2026 |
| FY2025 | Sep 30, 2025 | $8.82M | Dec 19, 2025 |
| FY2024 | Sep 30, 2024 | $3.11M | Nov 14, 2024 |
| FY2023 | Sep 30, 2023 | $8.02M | Dec 19, 2023 |
| FY2023 | Sep 30, 2022 | $12.59M | Dec 19, 2023 |
| FY2022 | Sep 30, 2021 | $12.26M | Dec 20, 2022 |
| FY2021 | Sep 30, 2020 | $4.30M | Dec 21, 2021 |
| FY2021 | Sep 30, 2019 | $1.90M | Dec 21, 2021 |
| FY2020 | Sep 30, 2018 | $934.4K | Dec 29, 2020 |
| FY2019 | Sep 30, 2017 | $103.2K | Dec 27, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Sep 30, 2014 | $1.29M | Jan 13, 2015 |
| FY2013 | Sep 30, 2013 | $755.0K | Jan 13, 2014 |
| FY2012 | Sep 30, 2012 | $1.64M | Nov 13, 2012 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 25, 2026 |
| FY2025 | Sep 30, 2025 | 0 | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 25, 2026 |
| FY2025 | Sep 30, 2024 | (7) | Mar 25, 2026 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 388.14M | Mar 25, 2026 |
| FY2025 | Sep 30, 2025 | 388.14M | Mar 25, 2026 |
| FY2025 | Sep 30, 2024 | 2.70M | Dec 19, 2025 |
| FY2024 | Sep 30, 2023 | 80.36M | Nov 14, 2024 |
| FY2023 | Sep 30, 2022 | 48.16M | Dec 19, 2023 |
| FY2022 | Sep 30, 2021 | 35.17M | Dec 20, 2022 |
| FY2022 | Jun 30, 2021 | 33.72M | Dec 20, 2022 |
| FY2021 | Sep 30, 2020 | 24.80M | Dec 21, 2021 |
| FY2020 | Sep 30, 2019 | 18.37M | Dec 29, 2020 |
| FY2019 | Sep 30, 2018 | 17.53M | Dec 27, 2019 |